ViGenCell Statistics

Total Valuation

ViGenCell has a market cap or net worth of KRW 54.71 billion. The enterprise value is 17.27 billion.

Market Cap	54.71B
Enterprise Value	17.27B

Important Dates

The last earnings date was Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

ViGenCell has 19.26 million shares outstanding. The number of shares has increased by 0.79% in one year.

Current Share Class	n/a
Shares Outstanding	19.26M
Shares Change (YoY)	+0.79%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	12.62%
Owned by Institutions (%)	4.05%
Float	12.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	195.76
PB Ratio	0.94
P/TBV Ratio	0.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.23
EV / Sales	61.91
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.57

Financial Position

The company has a current ratio of 5.73, with a Debt / Equity ratio of 0.13.

Current Ratio	5.73
Quick Ratio	5.69
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	-0.70
Interest Coverage	-42.17

Financial Efficiency

Return on equity (ROE) is -21.70% and return on invested capital (ROIC) is -13.24%.

Return on Equity (ROE)	-21.70%
Return on Assets (ROA)	-12.91%
Return on Invested Capital (ROIC)	-13.24%
Return on Capital Employed (ROCE)	-25.83%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	65
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.16% in the last 52 weeks. The beta is 1.08, so ViGenCell's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	-43.16%
50-Day Moving Average	2,719.10
200-Day Moving Average	3,291.38
Relative Strength Index (RSI)	46.12
Average Volume (20 Days)	207,692

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ViGenCell had revenue of KRW 278.95 million and -14.06 billion in losses. Loss per share was -731.00.

Revenue	278.95M
Gross Profit	-2.17M
Operating Income	-15.33B
Pretax Income	-14.06B
Net Income	-14.06B
EBITDA	-11.70B
EBIT	-15.33B
Loss Per Share	-731.00

Full Income Statement

Balance Sheet

The company has 45.18 billion in cash and 7.74 billion in debt, giving a net cash position of 37.44 billion or 1,943.52 per share.

Cash & Cash Equivalents	45.18B
Total Debt	7.74B
Net Cash	37.44B
Net Cash Per Share	1,943.52
Equity (Book Value)	58.03B
Book Value Per Share	3,012.18
Working Capital	37.88B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.90 billion and capital expenditures -112.54 million, giving a free cash flow of -11.01 billion.

Operating Cash Flow	-10.90B
Capital Expenditures	-112.54M
Free Cash Flow	-11.01B
FCF Per Share	-571.42

Full Cash Flow Statement

Margins

Gross Margin	-0.78%
Operating Margin	-5,495.85%
Pretax Margin	-5,038.79%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ViGenCell does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.79%
Shareholder Yield	-0.79%
Earnings Yield	-25.69%
FCF Yield	-20.12%

Stock Splits

The last stock split was on June 8, 2022. It was a forward split with a ratio of 2.

Last Split Date	Jun 8, 2022
Split Type	Forward
Split Ratio	2

Scores

ViGenCell has an Altman Z-Score of 2.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.92
Piotroski F-Score	n/a